Business Context and Reporting Period
Company: LeMaitre Vascular, Inc. (LMAT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A global provider of medical devices and human tissue cryopreservation services used primarily in vascular surgery. The company operates as a single segment, manufacturing products in Burlington, Massachusetts, and selling globally through a direct sales force and distributors.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $66.6 million | $59.9 million |
| Gross Profit | $48.4 million | $41.4 million |
| Gross Margin | 72.7% | 69.2% |
| Operating Income | $17.8 million | $12.6 million |
| Net Income | $15.7 million | $11.0 million |
| Diluted EPS | $0.68 | $0.48 |
| Cash from Operations | $15.1 million | $9.0 million |
| Cash & Equivalents | $26.9 million | $25.3 million |
| Short-term Marketable Securities | $340.4 million | $330.9 million |
| Total Debt (Convertible Notes) | $168.9 million (net) | $168.6 million (net) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% ($6.7 million) driven by higher average selling prices, increased unit volumes, and the European launch of the Artegraft bovine graft. Foreign exchange rates contributed an estimated $2.0 million increase.
- Margin Expansion: Gross margin improved by 350 basis points to 72.7%, attributed to price increases, manufacturing efficiencies, and a favorable product mix (specifically reduced sales of lower-margin porcine patches following the termination of the Elutia distribution agreement).
- Expense Trends: Operating expenses rose 6% to $30.6 million. General and administrative expenses increased 15% due to higher headcount and wages. Sales and marketing expenses rose 2% due to increased sales representative headcount.
- Geographic Performance: EMEA sales grew 20% and APAC sales grew 18%, outpacing the 7% growth in the Americas.
Outlook, Commentary, and Risks
- Dividends: The Board increased the quarterly cash dividend to $0.25 per share (from $0.20). A subsequent dividend of $0.25 per share was declared on April 28, 2026, payable June 4, 2026.
- Share Repurchase: On February 19, 2026, the Board authorized a $100 million share repurchase program valid through February 18, 2027. No repurchases have been made under this specific program to date.
- Convertible Notes: The company holds $172.5 million in 2.50% Convertible Senior Notes due 2030. The conversion rate was adjusted upward due to the dividend increase. The notes are not redeemable until February 5, 2028.
- Operational Initiatives: The company is transitioning allograft tissue processing from Fox River Grove to Burlington, expected to be complete by end of 2026. A new ERP system (Microsoft Dynamics D365) is being rolled out globally.
- Risks: Key risks include foreign currency fluctuations (44% of sales are non-USD), regulatory transitions (EU MDR and UKCA), and the ability to identify and execute acquisitions.
Investor Verification Checklist
- Dividend Impact on Debt: Verify the ongoing impact of the increased dividend ($0.25) on the conversion rate and potential dilution of the $172.5 million Convertible Senior Notes.
- Product Mix Sustainability: Confirm if the gross margin expansion is sustainable given the termination of the Elutia porcine patch distribution and the wind-down of other product lines (CardioCel 3D, DuraSure, AnastoClip).
- ERP Implementation: Monitor the rollout of the new ERP system in international locations for potential disruptions to financial reporting or operations.
- Regulatory Approvals: Track the status of the Artegraft and other product approvals in new territories (e.g., Germany tissue banking approval received Oct 2025) to validate growth projections.
- Foreign Exchange Exposure: Assess the sensitivity of future earnings to USD/Euro fluctuations, given that 44% of sales are generated outside the U.S.